贝伐-话题@MedSci

#贝伐#

228篇内容 | 4158人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1477072, encodeId=29f614e707295, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, objectType=article, longId=211375, objectId=15302113e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15302113e548, replyNumber=0, likeNumber=82, createdTime=2021-05-17, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15302113e548, moduleTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15302113e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477071, encodeId=e03d14e7071f9, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, objectType=article, longId=209932, objectId=aace20993238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aace20993238, replyNumber=0, likeNumber=76, createdTime=2021-04-15, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aace20993238, moduleTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aace20993238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477070, encodeId=4e4214e70701d, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布, objectType=article, longId=208886, objectId=8dd6208886d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd6208886d9, replyNumber=0, likeNumber=62, createdTime=2021-03-25, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd6208886d9, moduleTitle=“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd6208886d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477069, encodeId=44f014e706947, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后, objectType=article, longId=206293, objectId=d65b206293e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d65b206293e7, replyNumber=0, likeNumber=93, createdTime=2021-01-28, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65b206293e7, moduleTitle=J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65b206293e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477067, encodeId=bcae14e7067dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, objectType=article, longId=206110, objectId=c0bd206110aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0bd206110aa, replyNumber=0, likeNumber=96, createdTime=2021-01-24, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0bd206110aa, moduleTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0bd206110aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477068, encodeId=a9d514e706816, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, objectType=article, longId=206078, objectId=28d22060e857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28d22060e857, replyNumber=0, likeNumber=76, createdTime=2021-01-24, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28d22060e857, moduleTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28d22060e857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477066, encodeId=57e314e706686, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=NMPA批准BYVASDA（贝伐单抗生物仿制药）治疗复发性胶质母细胞瘤, objectType=article, longId=205139, objectId=3675205139af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3675205139af, replyNumber=0, likeNumber=92, createdTime=2021-01-02, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3675205139af, moduleTitle=NMPA批准BYVASDA（贝伐单抗生物仿制药）治疗复发性胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3675205139af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477065, encodeId=3bb014e7065d3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=30, createdTime=2020-11-25, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477064, encodeId=8b0214e706456, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, objectType=article, longId=203464, objectId=b4f620346485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f620346485, replyNumber=0, likeNumber=126, createdTime=2020-11-17, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f620346485, moduleTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f620346485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477063, encodeId=6e4514e7063ba, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, objectType=article, longId=202634, objectId=735d202634e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735d202634e5, replyNumber=0, likeNumber=73, createdTime=2020-10-31, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735d202634e5, moduleTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=735d202634e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477062, encodeId=305414e7062c8, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析, objectType=article, longId=202252, objectId=88af2022522e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88af2022522e, replyNumber=0, likeNumber=61, createdTime=2020-10-19, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88af2022522e, moduleTitle=Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88af2022522e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477061, encodeId=694714e70616c, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, objectType=article, longId=201078, objectId=94a22010e8b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94a22010e8b1, replyNumber=0, likeNumber=62, createdTime=2020-09-24, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94a22010e8b1, moduleTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94a22010e8b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477060, encodeId=b0eb14e70607b, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=复宏汉霖贝伐珠单抗上市注册申请获NMPA受理, objectType=article, longId=200558, objectId=090a200558bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=090a200558bc, replyNumber=0, likeNumber=64, createdTime=2020-09-12, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=090a200558bc, moduleTitle=复宏汉霖贝伐珠单抗上市注册申请获NMPA受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=090a200558bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477059, encodeId=7ddf14e70595a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化, objectType=article, longId=200286, objectId=f1bd20028653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bd20028653, replyNumber=0, likeNumber=110, createdTime=2020-09-06, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bd20028653, moduleTitle=东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bd20028653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477058, encodeId=c9d914e70587d, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=63, createdTime=2020-08-06, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477057, encodeId=17af14e7057fa, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Gynecol Oncol：依维莫司和贝伐单抗在复发性卵巢癌，腹膜癌和输卵管癌中的II期研究, objectType=article, longId=197252, objectId=947b19e25234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=947b19e25234, replyNumber=0, likeNumber=68, createdTime=2020-07-10, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=947b19e25234, moduleTitle=Gynecol Oncol：依维莫司和贝伐单抗在复发性卵巢癌，腹膜癌和输卵管癌中的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=947b19e25234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477056, encodeId=b65414e705683, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=三星Bioepis旗下贝伐单抗生物类似物AYBINTIO获CHMP正面评价, objectType=article, longId=196695, objectId=f3c819669568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3c819669568, replyNumber=0, likeNumber=63, createdTime=2020-06-30, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3c819669568, moduleTitle=三星Bioepis旗下贝伐单抗生物类似物AYBINTIO获CHMP正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3c819669568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477055, encodeId=373714e7055a1, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=信达生物贝伐珠单抗生物类似药——达攸同上市, objectType=article, longId=196189, objectId=c48d19618953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48d19618953, replyNumber=0, likeNumber=62, createdTime=2020-06-22, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48d19618953, moduleTitle=信达生物贝伐珠单抗生物类似药——达攸同上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48d19618953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477054, encodeId=d4e814e705477, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=NEJM：Atezolizumab联合贝伐单抗治疗不可切除肝癌, objectType=article, longId=194173, objectId=ddd31941e36c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddd31941e36c, replyNumber=0, likeNumber=87, createdTime=2020-05-16, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddd31941e36c, moduleTitle=NEJM：Atezolizumab联合贝伐单抗治疗不可切除肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddd31941e36c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477053, encodeId=c20c14e70535b, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, objectType=article, longId=193965, objectId=a65b19396562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65b19396562, replyNumber=0, likeNumber=77, createdTime=2020-05-13, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65b19396562, moduleTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a65b19396562)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐

2020-05-29

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌

2021-05-17

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好

2021-04-15

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布

2021-03-25

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后

2021-01-28

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效

2021-01-24

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案

2021-01-24

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

NMPA批准BYVASDA（贝伐单抗生物仿制药）治疗复发性胶质母细胞瘤

2021-01-02

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2020-11-25

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究

2020-11-17

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌

2020-10-31

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析

2020-10-19

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择

2020-09-24

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

复宏汉霖贝伐珠单抗上市注册申请获NMPA受理

2020-09-12

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化

2020-09-06

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2020-08-06

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Gynecol Oncol：依维莫司和贝伐单抗在复发性卵巢癌，腹膜癌和输卵管癌中的II期研究

2020-07-10

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

三星Bioepis旗下贝伐单抗生物类似物AYBINTIO获CHMP正面评价

2020-06-30

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

信达生物贝伐珠单抗生物类似药——达攸同上市

2020-06-22

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

NEJM：Atezolizumab联合贝伐单抗治疗不可切除肝癌

2020-05-16

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯

2020-05-13

科室
- - 订阅+
  - 更多科室
工具
服务